Skip to main content

Table 1 Study treatment arms

From: Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients

 

Day 1 to Day 14

Day 15 after anti-tuberculosis initiation

Day 14 after combined treatment (anti-TB and ART)

arm

Anti-tuberculosis alone

Combined anti-tuberculosis and ART

(for the duration of anti-TB therapy)

Pharmacokinetic monitoring

A

“300 mg rifabutin + standard ethambutol-isoniazid-pyrazinamide regimen” daily for 14 days

150 mg rifabutin every other day + standard ethambutol-isoniazid-pyrazinamide regimen combined with

ART regimen including 200/50 mg lopinavir/ritonavir taken twice daily

Blood taken for pharmacokinetic monitoring

B

“300 mg rifabutin + standard ethambutol-isoniazid-pyrazinamide regimen” daily for 14 days

300 mg rifabutin every other day + standard ethambutol-isoniazid-pyrazinamide regimen combined with

ART regimen including 200/50 mg lopinavir/ritonavir taken twice daily

Blood taken for pharmacokinetic monitoring